Prader-Willi Syndrome (PWS) is a rare genetic disorder characterized by a range of physical, mental, and behavioral problems. A key feature of PWS is a constant sense of hunger, leading to chronic overeating and obesity. The syndrome results from abnormalities in chromosome 15, where specific genetic markers are either missing or unexpressed.
The Methylation Specific PCR (MSP) test is a crucial diagnostic tool for identifying Prader-Willi Syndrome. This test focuses on detecting abnormal methylation patterns in the DNA associated with PWS. Methylation is a chemical modification of DNA that can affect gene expression without changing the DNA sequence. In the case of PWS, certain regions on chromosome 15 undergo abnormal methylation, leading to the syndrome's manifestation.
DNA Labs UAE offers this specialized MSP test for Prader-Willi Syndrome, providing a reliable means of diagnosis for families and individuals at risk. The test cost is set at 1970 AED. By conducting this test, healthcare providers can accurately diagnose PWS, enabling early intervention and management strategies to improve the quality of life for those affected by the syndrome.
The Sperm DNA Fragmentation (DFI) Test is a crucial diagnostic tool offered by DNA Labs UAE, aimed at evaluating male fertility potential. This test specifically measures the percentage of sperm cells that have fragmented or broken DNA, which can be a significant factor in understanding unexplained infertility, recurrent miscarriage, or failed IVF attempts. DNA fragmentation in sperm can be caused by various factors, including oxidative stress, lifestyle choices, infection, fever, and exposure to environmental and chemical toxins.
With a test cost of 1970 AED, the Sperm DNA Fragmentation DFI Test is conducted with precision and care at DNA Labs UAE, utilizing advanced technology to ensure accurate and reliable results. This information is critical for couples facing challenges in conceiving, as it can guide healthcare providers in recommending appropriate treatments or interventions to improve fertility outcomes. DNA Labs UAE offers this specialized service as part of its commitment to providing comprehensive fertility assessments, supporting individuals and couples on their journey to parenthood.
The Fragile X FMR1 Mutation Screen Test is a specialized genetic test designed to detect mutations in the FMR1 gene, which is associated with Fragile X syndrome. This condition is a genetic disorder that causes a range of developmental problems including learning disabilities and cognitive impairment. The test is crucial for individuals with a family history of Fragile X syndrome or for those showing symptoms of the disorder. By analyzing a sample of DNA, usually obtained from a blood draw, this test can identify variations in the CGG triplet repeat in the FMR1 gene that are indicative of Fragile X syndrome.
At DNA Labs UAE, this comprehensive testing service is offered for 1600 AED. The laboratory employs state-of-the-art genetic testing technologies to ensure accurate and reliable results. Conducting the test in a controlled environment under the supervision of experienced geneticists and technicians guarantees the highest standard of diagnostic precision. This test not only aids in the diagnosis of Fragile X syndrome but also plays a pivotal role in guiding the management and treatment of individuals affected by the condition. Furthermore, it can provide essential information for families considering their future reproductive options.
The "Galactosemia GALT Gene Mutation Detection Test" is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the GALT gene, which are responsible for galactosemia. Galactosemia is a genetic disorder that affects an individual's ability to metabolize the sugar galactose properly. The condition can lead to various health issues, including liver damage, growth problems, and intellectual disabilities if not diagnosed and managed early.
This test is crucial for early detection, enabling timely intervention and management to mitigate the adverse effects of the disorder. By analyzing DNA samples, the test identifies specific mutations in the GALT gene that are indicative of galactosemia, providing essential information for healthcare providers to develop an appropriate treatment plan.
Offered at a cost of 1600 AED, the test at DNA Labs UAE represents a significant step forward in the genetic diagnosis and management of galactosemia, offering hope and improved outcomes for affected individuals and their families.
The Amino Acids Quantitative Urine and Plasma 45 Amino Acids Full Panel Test, offered at DNA Labs UAE, is a comprehensive diagnostic assessment designed to evaluate the levels of 45 different amino acids in both urine and plasma samples. This test is crucial for detecting abnormalities in amino acid metabolism, which can indicate a variety of health issues ranging from nutritional deficiencies to more serious metabolic disorders. By analyzing the concentration of amino acids, healthcare providers can gain insights into a patient's metabolic state, helping in the diagnosis, management, and treatment planning of conditions such as aminoacidurias, organic acidurias, and urea cycle disorders. The cost of this extensive panel is 1940 AED, reflecting its value in providing a detailed overview of an individual's amino acid profile for medical evaluation and intervention.
The "FISH - MDS Panel - Chromosomes 5q, 7q, 8q, and 20q Test" is a specialized diagnostic examination offered by DNA Labs UAE, aimed at individuals suspected of having Myelodysplastic Syndromes (MDS) or related chromosomal abnormalities. This test employs Fluorescence In Situ Hybridization (FISH), a powerful cytogenetic technique that allows for the visualization of specific DNA sequences on chromosomes. By focusing on chromosomes 5q, 7q, 8q, and 20q, the test targets regions frequently associated with alterations in MDS cases. These chromosomal abnormalities can provide critical information regarding prognosis, potential response to therapy, and can also guide treatment decisions. The cost of the test is 1920 AED, reflecting the sophisticated technology and expertise required to perform this analysis. Through its precise targeting and the detailed genetic insights it offers, the test represents a valuable tool in the personalized management of MDS, enabling healthcare providers to tailor treatments to the unique genetic profile of each patient.
The Hepatitis C Viral Combo Test is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to detect the presence of Hepatitis C virus (HCV) in an individual's blood. This test is crucial for identifying both acute and chronic infections of HCV, a blood-borne virus that can cause liver disease, including cirrhosis and liver cancer. The combo test typically includes screening for HCV antibodies (anti-HCV) to determine past or present infection, as well as a nucleic acid test (NAT) for HCV RNA, which confirms active infection. Priced at 1920 AED, this test is a vital resource for early detection, enabling timely treatment and management of the condition, thereby reducing the risk of severe liver damage and associated health complications. DNA Labs UAE provides this test with a commitment to accuracy, confidentiality, and comprehensive support for those being tested.
The "Immunosuppressant Drug Profile 1 Test" is a specialized diagnostic examination offered at DNA Labs UAE, designed to monitor and measure the levels of certain immunosuppressive drugs in the bloodstream. This test is particularly crucial for patients who have undergone organ transplants or those being treated for autoimmune diseases, as it helps in ensuring that the dosage of immunosuppressant medication is optimal. By maintaining the right balance, the test aids in preventing organ rejection while minimizing the risk of drug toxicity.
The cost of the test is 1920 AED, reflecting the intricate nature of the analysis and the sophisticated technology utilized to achieve accurate results. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures reliability and precision, providing essential information for the effective management of immunosuppressive therapy. This test is a key component in the personalized treatment plans for patients requiring immunosuppression, enabling healthcare providers to make informed decisions regarding dosage adjustments and overall treatment strategies.
The "Immunosuppressant Drug Profile 4 Test" is a specialized medical examination offered by DNA Labs UAE, designed to measure the levels of certain immunosuppressant drugs in the bloodstream. This test is particularly crucial for individuals who have undergone organ transplantation or those being treated for autoimmune diseases, as it helps in ensuring that the dosage of immunosuppressant medications is optimal. By monitoring the concentration of these drugs, healthcare providers can adjust dosages to prevent organ rejection while minimizing the risk of drug toxicity.
The test covers a specific panel of immunosuppressant drugs, although the exact drugs included in "Profile 4" are not specified here. These drugs typically include agents like cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil, among others, which are commonly used to suppress the immune system in various clinical scenarios.
Administered at DNA Labs UAE, a facility known for its state-of-the-art diagnostic services, the test ensures accuracy and reliability in results. The cost of the "Immunosuppressant Drug Profile 4 Test" is set at 1920 AED. Given the critical nature of immunosuppressant therapy in transplant and autoimmune disease management, this test plays a vital role in patient care, ensuring that therapeutic levels are maintained for efficacy while reducing the risk of adverse effects.
The "Vibrio Cholerae Multiplex Detection and Differentiation of O1, Non-O1, O139, and Ctx Gene RNA Detection Qualitative Test" is a sophisticated diagnostic assay conducted at DNA Labs UAE, aimed at identifying and distinguishing between various strains of the Vibrio cholerae bacteria, which is responsible for causing cholera, a potentially life-threatening gastroenteric infection. This comprehensive test is capable of detecting the presence of the O1 and O139 serogroups, which are commonly associated with epidemic and pandemic outbreaks, as well as Non-O1 strains that are often linked to sporadic cases of cholera. Additionally, it includes the detection of the cholera toxin (Ctx) gene, a critical virulence factor in the pathology of the disease.
The test employs advanced molecular techniques to qualitatively assess the RNA of the Vibrio cholerae bacteria, ensuring high specificity and sensitivity in identifying the pathogen and its relevant strains. This is particularly important for public health surveillance, outbreak management, and guiding appropriate treatment strategies.
The cost of the test is set at 1900 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed. Conducted at DNA Labs UAE, a facility known for its state-of-the-art diagnostic capabilities and stringent quality standards, this test represents a critical tool in the fight against cholera, aiding in the rapid and accurate diagnosis of this disease.
